Beijing InnoCare Pharma announced it completed a $160 million financing to advance its portfolio of novel treatments for cancer and autoimmune diseases. In February 2018, InnoCare raised $55 million in a funding led by Vivo Capital. The company uses internal R&D, in-licensings and international collaborations to develop first-in-class and/or best-in-class drugs. It has three cancer candidates in clinical trials, including several tests for its BTK inhibitor. The latest investment round was led by Loyal Valley Capital.
Source:China Biotoday
